Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.

摘要: UNLABELLED Lenograstim is the glycosylated recombinant form of human granulocyte colony stimulating factor. The drug used to reduce risk life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy. accelerates neutrophil recovery significantly chemotherapy, beneficial effects on clinical end-points such as incidence laboratory-confirmed and length hospital stay. Chemotherapy dose intensity has also been increased receiving lenograstim, notably those breast or small cell lung cancer, although improvements tumour response survival have not demonstrated. assists undergoing bone marrow transplantation, stimulates production peripheral blood stem cells (PBSCs) for autologous transfusion aggressive mobilises CD34+ more efficiently unit terms than filgrastim successfully mobilise PBSCs from healthy donors allogeneic transplantation. Randomised trials shown increases rates disease remission lenograstim therapy acute myeloid leukaemia, no evidence stimulation malignant blasts. potential mobilisation nonmalignant autotransplantation chronic leukaemia. Other studies show efficacy lymphoblastic aplastic anaemia, children severe neutropenia reversal related antiviral AIDS, data are extensive. Cost analyses carried out a perspective, results inconclusive. Cost-effectiveness cost-benefit lacking at present. well tolerated, pain injection site reactions being reported most frequently trials. CONCLUSIONS confirmed valuable adjunct minimise haematological toxicity myelosuppressive chemotherapy disease. enhances rescue, PBSC mobilisation. Data indicate benefit disorders, blast proliferation. Further required assess fully pharmacoeconomic implications use other growth factors, provide management disease-related clarify its position relative filgrastim.